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What are the lessons learned from vaccine manufacturing in developing countries such as India, 



















Over a period of time, a tier of mostly middle-income developing countries has developed a 
considerable pharmaceutical and vaccine production capacity (WHO, 2011). However, outcomes 
have not always been positive for domestic manufacturers in developing countries. Economic 
and health lessons learned from vaccine manufacturing in developing countries include 
challenges and positive spillover effects. Evidence for this rapid review is taken from south and 
southeast Asia (India, Indonesia, Thailand, Vietnam), and Latin America (Brazil, Cuba, Mexico). 
Lessons learned to highlight include: 
• All seven of these countries are part of the Developing Countries Vaccine Manufacturers 
Network (DCVMN). India, Indonesia, Thailand, and Vietnam are known to have sizeable 
pharmaceutical industries (WHO, 2011). In Brazil, local vaccine companies have been 
successful, although it is not a very easy market (Parrish, 2020). Government support 
was found to be important (Brazil, Cuba). 
• Brazil and Cuba are good learning examples for vaccine production set-up by public 
institutions (Milstien et al., 2007; Milstien & Kaddar, 2010; WHO, 2015a), while India is an 
example for private manufacturers (Milstien et al., 2007; Kaddar  et al., 2014). 
Manufacture in Thailand and Vietnam has not developed to the same level as the more 
successful public sector manufacturers, despite concerted effort. 
• Regulation: As with other technology-driven industries, vaccine manufacturing is also 
highly-regulated by national policy and dominated by the private sector (WHO, 2015; 
Plotkin et al. (2017). Support from WHO is mostly technical; they have heavily supported 
regulatory system development in developing countries with vaccine manufacturing 
capacities, and they did this through creating institutional development plans based on 
National Regulatory Authority (NRA) assessment (Makenga et al., 2019). In Cuba, Brazil 
and India it was the development of vaccine production that pushed Governments to 
improve their NRAs.  
• Vaccine manufacturing remains a challenging and costly endeavour (Plotkin et al., 2017). 
The developing country vaccine market has historically been high volume, low 
profit traditional vaccines. This was not especially attractive to most vaccine-producing 
multinational companies (MNCs) (Milstien & Kaddar, 2010). Vietnam shows that 
emerging nations no longer limit their ambitions to attracting foreign direct investment 
(FDI) from European or North American companies, but seek to become innovative. 
• Public-private partnerships (PPPs) are vital for Thailand to accelerate vaccine 
development and production. However, this did not work for Mexico due to a history of 
political instability (Carrillo, 2017) - from the standpoint of self-sufficiency, not 
enough vaccines have been produced since 1998 (Tamez et al., 2016). 
• Pharma growth: India leads in terms of cheaper vaccines available for the country and 
internationally. A higher compound annual growth rate (CAGR) of the vaccine business 
than the pharma business may explain this. The pharma sector in Brazil has been a 
major contributor to the world’s vaccine advancements in R&D (Parrish, 2020).  
• Unlike the other countries in the Association of Southeast Asian Nations (ASEAN) region, 
Indonesia, Thailand and Vietnam are producing traditional vaccines domestically, with 
each pursuing its own priorities (Brückler, 2013). Vietnam will continue to have a negative 
vaccine trade balance due to its focus on catering to the domestic market (EVBN, 2014: 
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32). In Latin America, Mexico has not been so successful in local vaccine manufacture. 
The Cuban biotechnology sector is distinctive because it is owned by the state and not 
supported by speculative financing.  
• Data on positive spillovers effects focus on skills development. Technology transfer can 
also create positive spillover effects into associated industries and into the supporting 
public sector research infrastructure (IFPMA, 2015: 6). Estimated data for positive 
spillovers has been found (India, Brazil). However, studies that only estimate treatment 
effects without measuring spillover effects will underestimate the effectiveness of the 
intervention if positive spillovers are present (Benjamin-Chung et al., 2017). Although 
vaccines may cost more to develop than therapeutics, they also have the potential to 
provide far greater benefits to society (Xue & Ouellette, 2020). A systematic review on 
spillover effects on health outcomes in low- and middle-income countries (LMICs) found 
the strongest evidence for spillovers through reduced disease transmission, particularly 
vaccines and mass drug administration, e.g. in their National Immunisation Programmes 
(Indonesia, Brazil, Cuba).  
• There have been numerous successes in transferring new technology to existing vaccine 
manufacturers using public-private partnerships (e.g. India, Brazil, Indonesia). 
Manufacturers, notably those in Mexico and Brazil, as well as in other countries not 
traditionally associated with vaccine production, will opt for partnerships with 
multinational companies (MNCs) to access newer technologies. This route will 
normally not result in their development as innovative producers of vaccines; however, it 
can be seen as the best route to assure newer vaccines to their countries. 
• Technology transfer is an effective and efficient tool to reduce product development 
cost, and shorten the time-to-market. It has been used in India, Indonesia, Thailand, 
Brazil, and Mexico. Development of the Health Economic Industrial Complex in Brazil 
has helped to create jobs and national economic growth (WHO, 2011: 39). Vietnam has a 
good education system considering its level of development capable of producing an 
ample quantity of skilled labour that can participate in a wide range of manufacturing 
(Gintin, 2019). Indonesia has a lack of health-care workers (Milken Institute, 2016: 17). 
Scientists are hailed as heroes in Cuba, a prestige that helps limit brain drain 
despite low salaries and difficult conditions (Marsh, 2020). However, wage 
increases do not appear to be retaining a motivated workforce and boosting 
productivity in Cuba (O’Farrill, 2018). 
• Foreign direct investment (FDI) and trade: Vietnam manufacture has benefited from a 
progressive FDI policy; Indonesia, however, has not (Ginting, 2019). Special economic 
zones (SEZs) have been used in Thailand and Cuba to promote FDI in health-related 
activities. 
• Vaccine exports and imports: Some companies have formed partnerships with 
international players for the development of more niche vaccines to supply the global 
market (e.g. Cuba). India is the only one of the selected countries that has become 
vaccine self-sufficient (Lahariya, 2014). Therefore, export earnings for a number of 
vaccine manufactures in India are available (Saha, 2021). Indonesia currently buys and 
distributes vaccines for free at an estimated cost of about USD5.3 billion. India's reliance 
on pharma ingredient imports has risen over the past few decades due to the higher 
cost of domestic production (Nair, 2020). Research shows that exporting plasma results 
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in alternative processing using nucleic acid-based technologies support fast and flexible 
vaccine development and production (Rauch et al., 2018; Raw & Higashi, 2008). 
• Vaccine pricing: In Brazil, the Institute of Drug Technology (Farmanguinhos) plays a 
strategic role by acting as a regulator of market prices of antiretroviral drugs. However, 
market forces and parameters for vaccines are different from those for drugs 
(WHO, 2011: 5). Multinational companies (MNCs) can control pricing. The Serum 
Institute of India tends not to enter agreements with MNCs, as it wants to control the 
process and the market (Milstien et al., 2007). 
• Challenges: a lack of awareness and understanding of vaccines among the health 
community; limitations in affordability/ access, and constraints to manufacturing and 
supply have been found in India (Bhadoria et al., 2012). Lack of know-how is a 
possible main barrier to local vaccine production (e.g. Vietnam, Cuba). Lack of patents 
for novel vaccine concepts from several developing countries can be one of the 
obstructions to local production (e.g. Brazil). For more recently produced vaccines, and 
possibly for future vaccines, intellectual property may be an additional barrier to 
access (WHO, 2011). 
Although data on locally manufactured drugs on the balance of trade was available, this was not 
readily available for vaccine manufacturing. The evidence used in this review was taken from 
grey and academic literature, as well as interview with economic specialists. Although market 
reports on vaccine production are available for most of these countries, their data is not in the 
public domain.  
2. Introduction 
Economic impacts of local manufacture 
Pharmaceutical and vaccine production capacity has been developed over a period of 
time in some (mostly middle-income) developing countries (WHO, 2011: 6). Certain 
countries have achieved vaccine self-sufficiency. All seven of the countries included in this 
review are part of the Developing Countries Vaccine Manufacturers Network (DCVMN).1 Two of 
every three children born in the world are immunised with at least one vaccine from a DCVMN 
manufacturer (WHO, 2011: 12-13). When more vaccine manufacturers are able to enter the 
market, supply for countries increases while cost decreases. Increased DCVM competition has 
been shown to lower prices of vaccines (Padmanabhan et al., 2010).  
Positive spillover effects2 
Vaccines are almost always cost-effective in terms of public health outcomes (WHO, 2011: 
5). There is well-documented evidence of spillovers of many vaccines in developing countries 
(i.e. ‘herd effects’ - Edejer et al., 2005; Ozawa et al., 2012). This can justify the cost-effective 
 
1 This is a voluntary public health-driven alliance of vaccine manufacturers that aims to make a consistent supply 
of good-quality vaccines accessible to developing countries, especially the vaccines used in the World Health 
Organization (WHO) Expanded Program on Immunization (EPI). 
2 Spillovers are described using many different names in different subfields and disciplines – including treatment 
externalities, contamination, herd immunity, and indirect effects, among others. 
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scale-up of immunisation efforts to a global level via programmes, such as those with the 
Global Alliance for Vaccines and Immunization (Gavi, the Vaccine Alliance) (Benjamin-Chung et 
al., 2017). Benefits for individuals other than the vaccinated patient could defend the extra costs 
of vaccine development from a social welfare point of view (Xue & Ouellette, 2020). 
International spillovers are essential for developing countries to catch up with advanced 
economies, and this matter ranks high in the development policy agenda.3 However, studies that 
only estimate treatment effects without measuring spillover effects will underestimate the 
effectiveness of the intervention if positive spillovers are present (Benjamin-Chung et al., 2017).   
Challenges 
Emerging economies that have been making increasingly sophisticated vaccines now have 
experienced workforces, so know-how is less of a challenge (WHO, 2011: 30). However, 
maintaining that know-how may be an issue for some countries. Other details to consider 
include sustainable funding in a variety of areas along the value chain, or sustaining 
viability when exporting vaccines or producing new technology vaccines (Milken Institute, 2016: 
17). A fundamental relationship that has been the focus of many studies is the causal link 
between improved health and economic productivity. However, this is actually a challenging 
relationship to estimate rigorously (Dupas & Miguel, 2016: 4).  
3. India 
India currently is one of the leading manufacturers and suppliers of vaccines in the world. 
It accounts for approximately 60% of the total vaccines supplied to UNICEF, since the cost of 
manufacturing and clinical trials in India is relatively lower than in developed countries.4 Several 
vaccine institutes have been set up throughout the whole of the 20th and 21st centuries (Lahariya, 
2014).  
Capital support and framework 
A review of the history of vaccination in India by Lahariya (2014) shows vaccine manufacturing 
has moved from public to private units. Foreign direct investment (FDI) inflow to India has 
been on a long-term growth trend (UNCTAD, 2020: 41). Although analysis of data (for years 
2000 to 2019) shows that a larger share of the FDI equity (gross FDI includes equity, re-invested 
earnings, and other capital) has gone into services, these are mainly financial services, software, 
telecommunication, construction and trading than manufacturing (although drugs and 
pharmaceuticals manufacture are included).  
One example of a successful quasi-private sector manufacturer Shantha Biotechnics Ltd5, 
acquired by multinational company (MNC) Sanofi-Aventis, as well as partnering with an 
international public health group (International Vaccine Institute). Because of the competition, it 
 
3 World Bank (2010). Innovation Policy: A Guide for Developing Countries. World Bank Publications. The World 
Bank. 
4 Dr Anand Kumar, Managing Director Indian Immunologicals Ltd & Director Pristine Biologicals (NZ) Ltd. 
5 It was the first Indian company to develop, manufacture and market recombinant vaccine 
human healthcare products in India. It caters to major international markets including Asia-Pacific, Africa, 
Commonwealth of Independent States, and Latin American countries in addition to international organisations 
UNICEF and the Pan American Health Organization (PAHO). 
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has been able to reduce costs of quality vaccines. Since 2013, Shantha Biotechnics’s impact on 
public health through the supply of oral cholera vaccine to WHO has contributed significantly to 
global cholera control.6 Strong regulation, as well as significant infusion of, improvement and 
standardisation of technology through collaboration with the non-profit aided in its success. US 
National Institutes of Health's (NIH) National Cancer Institute (NCI) and Johns Hopkins also 
partnered with Shantha Biotechnics to commercialise L2-based HPV vaccine technology and 
improve access in resource-poor settings (Padmanabhan et al., 2010).  
However, a number of factors have been found to subdue the growth and penetration of vaccines 
in India, both in the public and private markets: 
• vaccine manufacturing entails high fixed costs, amounting to 60% of total cost; the 
need for scale trumps any labour cost advantages in emerging markets (Bhadoria et al., 
2012: 18); 
• while Indian vaccine manufacturers are increasingly sophisticated about managing 
innovation, they feel challenged in their ability to interpret patent claims or to 
challenge dubious ones (Milstein et al., 2007; Padmanabhan et al., 2010). Thus, they 
dedicate more time and resources to “invent around” the patent rather than risking 
infringement, that is, to avoid the use of the specific technology or avoid production of 
the product altogether; 
• there are difficulties in introducing new vaccines into the country’s massive 
universal immunisation programme (UIP). Vaccines are provided free under the UIP, 
but only for a few highly communicable and life-threatening diseases. The Indian 
Government usually includes a vaccine in the UIP only when it is priced at less than a 
few US dollars per dose (Bhadoria et al., 2012: 20), and 
• obtaining vaccines through the private system can be expensive. Hence some 
newer vaccines, for e.g. pneumococcal vaccine, can be afforded only by GSS7, when 
the cost is lowered by local manufacturing. A compounding factor is that in India, most 
medical insurance policies (including corporate insurance) do not cover 
vaccination, unlike in China and developed countries.  
Pharma growth and vaccine access 
The Indian vaccine market has exhibited strong recent growth. It reached a value of INR59 
billion in 2016, growing at a compound annual growth rate (CAGR) of nearly 18% during 2009-
2016. As noted by the latest market report by IMARC Group,8 the Indian vaccine market size 
reached INR94 billion (USD1.3 billion) in 2019. It is predicted to reach INR252 billion (USD3.5 
billion) by 2025, encouraged by significant assistance from the Government. 
 
6 Shailesh Ayyangar, Managing Director – India and VP – South Asia, Sanofi. 
7 Globals, Strivers and Seekers defined as those with an annual household income of greater than INR2 lakh 
(USD 2,746) based on 2000 prices. The Globals are the super-rich elite; the Strivers and Seekers constitute 
the middle class. 
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The Indian pharmaceutical industry is reported to be the third largest in the world in terms of 
volume, and 14th largest in terms of value.9 Indian production also dominates its domestic 
pharmaceutical market, with several biologicals manufactured in abundance, and at affordable 
prices. The country has retained self-sufficiency through indigenous production of 
formulations (Lahariya, 2014).10 Serum Institute of India’s newly licenced pneumococcal 
vaccine PNEUMOSIL is an important addition to their arsenal because it’s designed to provide 
the same level of protection as the other WHO-prequalified (PQ)11 pneumococcal conjugate 
vaccine (PCVs), but at the unprecedentedly low Gavi price of USD2 per dose (or USD6 per 
child).12 Currently, the pharmaceutical industry has been freeing up capacity, and pushing ahead 
with investments to help support a global vaccination campaign for COVID-19.13  
Vaccine export and imports 
India continues to be one of the leading exporters of formulations or generic medicines to 
the global market.14 Official data shows India’s pharmaceutical exports of USD19.27 billion and 
imports in 2018-19 was USD10.43 billion with exports of USD19.27 billion (Nair, 2020). Research 
shows that India is eager to emerge as a reliable alternative China, to bail out countries that have 
caught up in China’s new export rules for active pharmaceutical ingredients (APIs) (Nair, 2020). 
Some Indian companies now produce for export with large MNCs: 
Case studies:  
• Bharat Biotech International Ltd started operation in 1996. In a short span, it has 
become a leading biotechnology company, with over 160 patents. It became the largest 
rabies vaccine producer after the acquisition of Chiron Behring from the MNC 
GlaxoSmithKline (GSK) in March 2019. Net sales for FY19 were INR 763.3 crore 
(USD105 million), while net profit was INR 111.6 crore (USD 15.4 million). Due to its low 
base, the growth figures are impressive: the five-year net sales CAGR was 23.6% while 
the same for net profit was 43.3%. Its export earnings were 37% of its net sales in 2019 
(Saha, 2021). 
• Cadila Healthcare, the fifth largest pharmaceutical company in India, produces COVID-
19 treatment drugs like Remdesivir. It is also developing an indigenous vaccine for the 
novel coronavirus. It has received Government approval for phase-III trials on 26,000 
Indian patients. Its consolidated net sales for FY19 were INR 14,253.1 crore (USD 1.9 
million), while net profit for the financial year was INR 1,176.1 crore (USD 162,003). More 
 
9 Special Report: India’s Pharmaceutical Industry: https://glintpay.com/special-reports-en_us/special-report-
indias-pharmaceutical-industry/  
10 The country was made self-sufficient for tetanus anti-toxin and anti-snake venom serum, followed by DTP 
(Diphtheria, Tetanus and Pertussis) group of vaccines, and then later on MMR (measles, mumps and rubella) 
group of vaccines. 
11 WHO prequalification (PQ) ensures vaccines used in immunisation programmes are safe and effective. It 
provides Member States and procurement agencies, such as Gavi, the Global Fund and UN organisations like 
UNICEF, with the information required to purchase vaccines matching the specific needs of the programme: 
https://www.who.int/medicines/regulation/prequalification/prequal-vaccines/about/en/ 
12 PATH (2020). Vaccine options for preventing pneumonia just got better in India. 18 August 2020: 
https://www.path.org/articles/vaccine-options-preventing-pneumonia-just-got-better-india/  
13 India to continue export of medicines, including vaccines: PM Modi. 9 January 2021: 
https://www.reuters.com/article/india-modi-idUSKBN29E084  
14 In the case of raw materials – intermediaries and APIs – China enjoys the number one position on the global 
stage. 
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than one-third of its revenue earnings are from exports (Saha, 2021). However, Cadila’s 
pricing details for the vaccine are unavailable. 
• Pune-based Serum Institute of India: established in 1966, is ranked as India's leading 
biotechnology company, with over 1.5 billion doses produced in several available 
facilities and sold. Vaccines are also accredited by the World Health Organization 
(WHO) Geneva, and are being used in approximately 170 countries across the globe in 
their National Immunisation Programmes.15 In 2018-19, its net sales were at INR 5,238 
crore (USD 721,576), while profit after tax was INR 2,252 crore (USD 310,231). The five-
year (2014-2019) CAGR for sales was 8.1%, while the five-year CAGR for profit after tax 
was 5.3%. Its export earnings were over two-third of its net sales in 2019. Total assets 
were INR 16,703 crore (USD 2.3 million) at the end of 2019 (Saha, 2021). Serum 
Institute of India tends not to enter agreements with MNCs, as it wants to control the 
process and the market (Milstien et al., 2007).16 Currently, the Indian Government has 
been negotiating with the Serum Institute of India to bring down the price 
of AstraZeneca's COVID-19 vaccine, before clearing any shipments for exports or private 
sales.17 
However, India's reliance on pharma ingredient imports has risen over the past few decades 
due to the higher cost of domestic production. The price gap with China has reached as much as 
20-30%, particularly for energy-intensive fermentation-based ingredients used in anti-infective 
vaccines (Nair, 2020). 
Positive spillover effects 
There are limited positive spillover effects noted in the literature: only one trial intervention 
by Sur et al., (2009) reported positive spillover estimates for typhoid vaccine (44% decrease in 
typhoid, no deaths or health events related to typhoid) (Benjamin-Chung et al., 2017). 
Skills development 
Technological advancements and improved cold chain storage facilities have led to 
increased vaccine production capacity in the country. However, in terms of skills, research shows 
that there has been a limited focus on training in vaccinology and immunology in India 
(Lahariya, 2014). In 2010, the India Vaccinology Course (INDVAC)18, was implemented as an 
educational method to address the need for knowledge and research. However, the course is 
aimed at specialists already working in vaccinology.  
 
15 https://www.seruminstitute.com/about_us.php  
16 The dominance of the multinational companies in the vaccine trade market (e.g. GSK, Pfizer, Merck Sharp & 
Dohme [MSD]) was predicted to subside in the coming years; however, this was before the COVID-19 epidemic. 
17 The vaccine would be priced at about INR1,000 (USD13.55) per dose for the private market in India and would 
cost the Government approximately INR250 (USD3.40) per dose: 
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/bharat-biotech-pursues-covid-
19-vaccine-approval-in-over-40-countries/articleshow/81085493.cms  
18 http://www.indvac.org/  
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4. Indonesia  
The state-owned company Bio Farma is the only vaccine and serum manufacturer 
in Indonesia. Its traditional focus has been on commodity type paediatric vaccines.19 
Vaccination through the National Immunization Program (NIP) is compulsory in Indonesia (Milken 
Institute, 2016: 7). Founded to serve the local market, it was the first ASEAN-based vaccines 
manufacturer to achieve WHO PQ status, enabling participation in UNICEF tenders for DTP, 
DTP-HepB, HepB, measles, and oral polio vaccines (Brückler, 2013). Although NIP costs are 
covered by its universal health-care system (or JKN, Jaminan Kesehatan Nasional); any 
vaccines not included in the government programme must be paid for out of pocket. 
Private health insurance may not cover them either (Milken Institute, 2016: 7).  
Capital support and framework 
Indonesia is new to self-financing its vaccine manufacturing sector. Indonesia is 
transitioning from donor-based funding because it has become more affluent, and is now a 
middle-income country according to the 2020 World Bank classifications. Therefore, it is no 
longer considered a priority country for global donors. Extensive support from Gavi ended in 
2018 (Fonjungo et al., 2020: 2; Milken Institute, 2016: 7). In the past, as much as 98% of Bio 
Farma’s research funds came from abroad, with the Netherlands, Germany, Australia and South 
Africa being the biggest sources.20 The European Union poured aid into the Indonesian health 
sector from the 1980s, but stopped in early 2014 due to this new affluence.21 This has resulted 
in an increase in the role of Government in the Indonesian healthcare industry. The 
Government has been able to provide more money to develop the country’s universal healthcare 
system: IDR100 billion (USD 7.7 million) through the country’s Ministry of State-owned 
enterprises was allocated in 2010, however, this was only able to support five years of basic 
vaccine research. 
Pharma growth and vaccine access 
Indonesia is one of the fastest growing pharmaceutical markets in Asia, but the 
biopharmaceutical industry is in the nascent stage.22 The pharmaceutical market is worth 
USD6 billion. According to Global Data, it is ranked the largest market in the ASEAN regions, 
with the market value expected to reach IDR141.6 billion (USD10.11 billion) by 2021. Beyond 
traditional vaccines, Indonesia's exposure to H5N1 influenza and its resulting contributions to 
global influenza outbreak monitoring have driven further vaccine developments (Brückler, 2013).  
There are several major players in the Indonesia pharmaceutical market.23 The majority of 
pharmaceutical companies are located in West Java and Jakarta due to favourable tax 
 
19 It developed the 5-in-1 shot pentavalent vaccine which protects against DTP, hepatitis B, and Hib. 
20 Indonesia is becoming a global vaccine player, but so is China. 8 April 2015: 
https://www.manufacturingchemist.com/news/article_page/Indonesia_is_becoming_a_global_vaccine_player_but
_so_is_China/107395  
21 Dr Carole Brückler, Head of Asia-Pacific operations for Deallus Consulting in Singapore. 
22 Ken Research (2018). Indonesia Pharmaceutical Market Outlook to 2022: 
https://www.kenresearch.com/healthcare/pharmaceuticals/indonesia-pharmaceutical-market/143542-91.html  
23 These include: PT Kalbe Farma; PT Sanbe Farma; PT SOHO Global Health; PT Dexa Medica; PT Pharos; PT 
Kimia Farma; PT Tempo Scan Pacific Tbk; PT Merck Tbk; Fahrenheit; Sanofi Aventis, PT Novell Pharmaceutical 
Laboratories; Biofarma; Darya Varia, and Konimex. 
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incentives,24 well-developed infrastructure, and greater access to medicinal herbs. Broadly 
speaking, FDI to manufacturing in Indonesia had been decreasing in the last few years (Ginting, 
2019).25 However, latest records show that total FDI in Indonesia is rising: FDI inflows to 
Indonesia grew by 14% to a record level of USD23 billion, with strong investments in 
manufacturing (UNCTAD, 2020: 43).  
Vaccine exports and imports 
World Bank trade statistics26 show that Indonesia is the biggest vaccine exporter in 
Southeast Asia. The country earned USD76.3 million from vaccine exports in 2010, which grew 
by 25.2% to USD95.5 million in 2019. Indonesia currently buys and distributes vaccines for 
free at an estimated cost of about USD5.3 billion.27 To date, every vaccine used in Indonesia’s 
NIP is manufactured by Bio Farma, whose “commitment was to develop national vaccine 
industry’s independence, such that the Government is not required to import vaccines to 
fulfil national needs”.28 However, this has now changed due to COVID-19.29  
Positive spillover effects 
There is limited evidence on positive spillover effects of vaccine manufacture. A family 
may not be able to afford a vaccine, but the Conditional Cash Transfer (CCT) programme could 
make this possible (Milken Institute, 2016: 14). Research by Kusuma et al. (2017) shows that 
Indonesia’s large-scale household CCTs scheme known as Program Keluarga Harapan (PKH) 
significantly contributed to an increase in child vaccination rates for most vaccines, particularly in 
the treatment group (up to 30%). However, data on potential spillovers of this programme is 
unavailable. 
Skills development 
Bio Farma's credits its success to committed project management, and availability of 
competent staff. As Bio Farma vaccines are WHO pre-qualified, they also have access to the 
global skills market through international partnerships.30 For example, through a technology 
transfer from the Biken Institute of Japan, together with WHO and BioFarma all worked towards 
developing influenza vaccines during the 2009 pandemic (Brückler, 2013). Bio Farma has also 
 
24 Indonesia passed the so-called "omnibus law" in October 2020, that promised to eliminate red tapes and 
streamline the country's investment process.  
25 Most FDIs to Indonesia in the last few years have been channelled to non-manufacturing sectors. Only at 
number 10 of the destination of FDIs in Indonesia does a manufacturing sector feature, however, this is the 
automotive industry. 
26 World Integrated Trade Solution: https://wits.worldbank.org/  
27 Jefriando M, Widiant S (2021). Indonesia may allow private sector to buy and distribute vaccines. 14 January 
2021: https://www.reuters.com/article/us-health-coronavirus-indonesia-vaccine-idUSKBN29J1ET  
28 Bachtiar NS, Nurlaela N (2014). Sejarah perkembangan produksi vaksin di Bio Farma, Indonesia [History and 
development of vaccine production in Bio Farma, Indonesia]. Immunization program in Indonesia: History and 
Development. Jakarta. 
29 Indonesia is importing China’s Sinovac Biotech Ltd COVID-19 vaccine. Sinovac will also ship raw material for 
45 million doses, which Indonesia’s state pharmaceutical firm Bio Farma will process locally. Besides Sinovac, 
the Government has orders with at least three other vaccine suppliers, including AstraZeneca Plc. Indonesia may 
allow companies to procure their own COVID-19 vaccines for their staff, to further reduce the economic burden 
on the state. However, this may discriminate those from lower-incomes. 
30 Dr Ahd Hamidi, bioprocess technologist: http://dx.doi.org/10.2471/BLT.19.031219  
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formed partnerships with international players for the development of more niche vaccines to 
supply the global market, e.g. co-operation with Australia’s Murdoch Children’s Research 
Institute in the development of a rotavirus vaccine.31 However, the long-term challenges in the 
inflexible labour market needs to be addressed to improve vaccine manufacture. Schools and 
colleges have to produce graduates with better skills, to match with industry needs. Additionally, 
Indonesia’s export-oriented sectors not only need an FDI-friendly policy, but also progressive 
Government policies to attract manufacturing investors (Ginting, 2019).  
5. Thailand  
The state enterprise Government Pharmaceutical Organization (GPO) manufactures 
vaccines in Thailand (WHO, 2011: 24). Data from 2016 shows that the organisation produces 
drugs at two government-owned factories.32 Thailand has held vaccines capabilities in small 
scale settings since 1953, with the set-up of a BCG vaccine production at Queen Saovabha 
Memorial Institute (QSMI). Since 2010, BIOVALYS33  biopharmaceutical company focuses on 
finding partners that are quality vaccine manufacturers. 
Capital support and framework 
Procurement of vaccines and the immunisation programme is financed mainly by the 
Government, i.e. the National Health Security Office (NHSO) through its tax payments to 
primary care facilities. This includes distribution of vaccines to all health care facilities in the 
universal health coverage (UHC) scheme (Coe & Gergen, 2017: 10). The UHC scheme finances 
all vaccines under the EPI, which helps ensure its long-term financial sustainability.34 
Government-use licences on vaccines (ARVs) disseminated are issued under the authority of the 
Ministry of Health (MoH) (WHO, 2011: 39). The National Program for Immunization produces 
and distributes vaccines for its Expanded Program of Immunization (EPI), but is fiscally 
constrained from adding new vaccines. New products are subject to a long and complicated 
approval process before being included in the program, or are only available in the private 
market (Milken Institute, 2016: 9). However, the one-sided health financing system by the 
NHSO comes with its own dangers. In the event of an economic downturn, the tax base could be 
squeezed, threatening health financing (Coe & Gergen, 2017: 12). The costly vaccine 
procurement will make vaccines generally prohibitive to the average consumer (Milken Institute, 
2016: 7). 
Public-private partnerships (PPPs) are vital for Thailand to accelerate vaccine development 
and production. It includes seeking appropriate partners within and outside the country, given 
that private firms in Australia, India, Indonesia, and some other countries in the region are 
experienced in the field of vaccine development and production. Although PPPs are already 
 
31 Indonesia is becoming a global vaccine player, but so is China. 8 April 2015:  
https://www.manufacturingchemist.com/news/article_page/Indonesia_is_becoming_a_global_vaccine_player_but
_so_is_China/107395  
32 "Our Factories". Government Pharmaceutical Organization (GPO). Archived from the original on 5 February 
2016: http://ggtcf.blogspot.com/2019/04/government-pharmaceutical-organization.html  
33 https://www.biovalys.com/our-company/  
34 Thailand's New National Vaccine Strategy. 28 June 2011: https://www.nbr.org/publication/thailands-new-
national-vaccine-strategy-building-capacity-accelerating-production/  
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addressed as part of the new National Vaccine Strategy,35 there are very few cases of such 
partnerships at the initial phase of the R&D process. One example is GPO-Mérieux, the joint 
venture between the Thai government and Sanofi-Pasteur, to manufacture innovative vaccines 
that meet regional needs. This PPP is unique in the ASEAN region. Sanofi-Pasteur's 
Japanese encephalitis vaccine (JEV) has been developed through regional clinical development 
and transfer of all manufacturing steps after bulk vaccine production to its Thai facility (Brückler, 
2013). Also, Biovalys has successfully joined QSMI, BioNet-Asia Co., Ltd, and Liaoning Cheng 
Da Bioechnology Co Ltd (CDBIO) to manufacture rabies vaccine (TRCS CPRV) and supply in 
Thailand and ASEAN countries. 
Pharma growth and vaccine access 
Thailand ranked 7th in the top 10 investor economies by FDI stock in 2013 and 2017 (UNCTAD, 
2019: 71). The 131% growth in outward FDI stock from Thailand to LDCs was due to the 
country’s investment in ASEAN economies, in particular in Myanmar (USD4.2 billion in 2017) and 
the Lao People’s Democratic Republic (USD3.4 billion) (UNCTAD, 2019: 69). 
Thailand is not vaccine self-sufficient, but is putting plans in place to be. Thailand 
embarked on a National Vaccines Strategy in 2011, aiming not just to become self-sufficient but 
also to meet regional needs of vaccines for ten diseases (Brückler, 2013). The plan includes 
recommendations for human resources, infrastructure development, and domestic production. If 
production succeeds, Thailand would be able to produce most of the essential vaccines for use 
in their EPI system. In 2020, the EPI programme added Rota vaccine for children 2- and 4-
months of age.36  However, the country produces only two of the vaccine antigens scheduled in 
the EPI - although data is only available from 2011.37 
Siam Bioscience38 is the first and only biopharmaceuticals manufacturer in Thailand. It is owned 
by the Thai king’s vast business holdings. The group, established since 2009, consisted of two 
major companies: Siam Bioscience Co Ltd. and Apexcela Co Ltd. Apexcela focuses on sales, 
marketing, and distribution of Siam Bioscience products, including business developments 
aiming to build partnerships both in Thailand and worldwide. In 2017, Siam Bioscience Group 
expanded business further by establishing two subsidiaries – one based in Cuba.39 Thailand is 
planned to be the Oxford University COVID-19 vaccine production base for the ASEAN 
region. Out of the 1 trillion baht (USD33 billion) allocated to public health in the 2021 fiscal 
budget, 40 billion baht (USD1.3 billion) has been set aside to for COVID-19 related measures, 
 
35 Dengue, diphtheria, tetanus, pertussis, mumps, measles, encephalitis, polio, hepatitis B, and tuberculosis. 




37 Thailand's New National Vaccine Strategy - Building Capacity, Accelerating Production. Interview with Yot 
Teerawattananon. 28 June 2011: https://www.nbr.org/publication/thailands-new-national-vaccine-strategy-
building-capacity-accelerating-production/  
38 https://www.siambioscience.com/?lang=en  
39 Inno Biocosmed Co., Ltd. and Abinis Co., Ltd. (the joint venture company with CIMAB (Cuba) for R&D, 
manufacturing, and commercialisation of mammalian cell culture derived focus on exportation). 
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such as production of a vaccine.40 In February 2021, Siam Bioscience became one of 25 
companies chosen by AstraZeneca to become its manufacturer of the COVID-19 vaccine.41 
Vaccine exports and imports 
Thailand's pharmaceutical export value was USD474.5 million in 2019. It is forecast to rise to 
USD502 million by 2024 with a five-year CAGR of 3.1% in local currency terms, and 1.1% in US 
dollar terms.42 Special economic zones (SEZs) promote FDI in health-related activities. These 
zones prioritise manufacturing of medical devices and pharmaceuticals (OECD, 2020: 14). 
The Industrial Estate Authority of Thailand (IEAT),43 a state-enterprise under the Ministry of 
Industry, has established 12 special IEAT “free trade zones” reserved for industries 
manufacturing exclusively for export.44 Besides Thailand, GPO markets its products in Nigeria, 
Ghana, Bhutan, Somalia, Myanmar, Sri Lanka, Malaysia, Cambodia, and Vietnam.45 GPO will 
produce the anti-retroviral (HIV vaccine) Efavirenz - sold under the brand name Sustiva, amongst 
others - after receiving WHO approval. GPO's product costs 180 baht  (USD 6) per bottle of thirty 
600mg tablets. The imported version retails for more than 1,000 baht (USD 33) per bottle. GPO 
will devote 2.5% of its manufacturing capacity to make 42 million Efavirenz pills in 2018, allowing 
it to serve export as well as domestic markets. The Philippines alone will order about 300,000 
bottles of Efavirenz for 51 million baht (USD1.7 million).46 
Since 2010, GPO-MBP, a joint venture between the Government Pharmaceutical 
Organization and Sanofi Pasteur, supplied approximately 800,000 doses of seasonal influenza 
vaccine by formulating and filling imported bulk, and the remaining 1.3 million doses were 
imported as finished products (Pitisuttithum & Wirachwong, 2019). Thailand is now focusing on 
local production possibilities rather than importation of new vaccines, with support from 
Gavi (Makenga et al., 2019).  
Positive spillover effects 
Thailand has a bold vision for growth, however there is no evidence on positive spillover effects. 
Skills development 
For the 2009 H1N1 influenza pandemic, technology transfer was an important factor. The non-
profit PATH International provided licensure dossier preparation assistance, as well as 
 
40 Oxford picks Thailand as production base for Covid-19 vaccine. 19 October 2020: 
https://www.nationthailand.com/news/30396412?utm_source=category&utm_medium=internal_referral  
41 Siam Bioscience was selected by AstraZeneca. 18 February 2021: https://www.thaipbsworld.com/siam-
bioscience-was-selected-by-astrazeneca/  





43 https://www.ieat.go.th/en  
44 THAILAND: FOREIGN INVESTMENT: https://santandertrade.com/en/portal/establish-
overseas/thailand/foreign-investment  
45 Company Overview - Government Pharmaceutical Organization: http://www.intergpomed.com  
46 Wipatayotin A (2018). "Thailand gets nod to make HIV/Aids drug". Bangkok Post. 3 November 2018. 
https://www.bangkokpost.com/thailand/general/1569426/thailand-gets-nod-to-make-hiv-aids-drug  
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production and process development (PATH, 2018: 7). A sub-license agreement with made with 
WHO to obtain Russian live attenuated influenza vaccine (LAIV) technology from the Institute of 
Experimental Medicine (IEM)47 in Saint Petersburg, Russia (Pitisuttithum & Wirachwong, 2019). 
IEM provided methodological support to the scientific team in Thailand.  
The 2018 Smart Visa programme is a more recent method set-up to attract high-skilled experts, 
investors, and employees of foreign start-ups in high-tech medical devices to Vietnam (OECD, 
2020: 14). However, there is no evidence available to show how successful this has been for 
vaccine manufacture. 
Manufacturing makes up 42.9% of main invested sectors. With an increased recognition that 
macroeconomic liberalisation and an economy driven by manufactured exports would not ensure 
sustainable growth, Thai policy makers and firm managers belatedly shifted their attention to 
technology matters and human resource development, on ways in which FDI can be 
leveraged more strongly to support manufacture (IMF, 2002: 11). However, there is no data 
available for vaccine manufacture. Also, retaining vaccine know-how is an issue: employee 
turnover in the health-care industry is high. Some work on a volunteer basis, while others receive 
low salaries. 
6. Vietnam 
Vietnam’s domestic manufacturing has historically been successful, and it is practically 
self-sufficient. The first vaccine produced in Vietnam was oral polio vaccine (OPV) in the early 
1960s, which contributed to polio eradication in Vietnam in 2000 (Pagliusi et al., 2014). Vietnam 
eliminated neonatal tetanus in 2005, and has controlled measles and hepatitis B spread (Pagliusi 
et al., 2014). Since 2006, there have been no whooping cough fatalities. Vietnam has been 
conservative in prioritising new vaccines (ThinkWell, 2017: 5). However, the Expanded 
Program on Immunisation (EPI) was launched in Vietnam in 1985 with six vaccines, and by 2015 
was expanded to 12 vaccines.48 All EPI vaccines used in Vietnam are domestically 
produced, with the exception of two imported products. 
Manufaturing capabilities are shared over four Government-backed institutes, using 
equipment and technology that meets Current Good Manufacturing Practice (cGMP)-WHO 
standards, with each institute building up its own specialties (Nhan Dan, 2020):  
• Company for Vaccine and Biological Production No.1: The state-owned limited company 
VABIOTECH was originally established by the Vietnamese Minister of Health in March 
2000. It is the biggest vaccine manufacturer and supplier for the National EPI in Vietnam. 
VABIOTECH currently produces vaccines against hepatitis A, hepatitis B, Japanese 
encephalitis, and cholera;  
• Da Lat Pasteur Vaccines Company Ltd: the Dalat Pasteur facility was incorporated as the 
Dalat Pasteur Vaccines Company Limited (DAVAC) in 2010; 
 
47 http://www.iem.cas.cz/en/  
48 Tuberculosis, diphtheria, pertussis, tetanus, hepatitis B, measles, polio, Japanese B encephalitis, cholera, 
typhoid, rubella, and Haemophilus Influenza Type b (Hib). 
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• MoH’s Centre for Research and Production of Vaccines and Biology: POLYVAC has 
been prequalified by WHO and is at the vanguard of the country’s efforts to improve the 
quality and targeting of its products, and 
• Institute of Vaccines and Medical Biologicals: IVAC has been producing vaccines in 
Vietnam for several years. Since 2010, IVAC has been working to develop and license 
vaccines against both seasonal and pandemic influenza. This will be a critical 
achievement because Vietnam is uniquely vulnerable to A/H5N1 (Regan, 2018). 
However, as a result of improvements in health status, the country is undergoing several 
epidemiological transitions. Obstacles that pharmaceutical manufacturers must face when 
launching new products into Vietnam’s pharmaceutical marketplace are listed below: 
• the health system is facing a number of challenges, not least of which is the widespread 
withdrawal of external funding support for continuing health care activities (WHO, 
2017: 1); 
• comparing prices for domestic vaccines versus alternative international commercial 
products is complicated by the way in which the MoH fixes prices for domestic 
vaccine products49;  
• the challenge of establishing reliable independent financing for the EPI vaccines (i.e. 
secure 100% funding from Government of Vietnam sources) will remain a critical issue 
for coming years that will constrain the available MoH budget to work on non-priority 
diseases, such as seasonal influenza (WHO, 2017: 16); 
• establishing a system for post-marketing surveillance will be an important challenge for 
obtaining PQ status (WHO, 2017: 19);  
• the pricing structure negatively impacts the amount of resources available for R&D, 
and for reinvestment into company infrastructure (for example, to maintain GMP 
status) (WHO, 2017: 21). Neither POLYVAC nor the other state-owned operations 
have negotiating power to change the vaccine pricing scheme, and these policies 
pose challenges for corporate financial management; 
• further adaptations to meet WHO global export standards are necessary, such as 
the WHO certification of the Vietnamese NRA and the GMP certification of production 
sites, which are time- and resource-intensive changes (Brückler, 2013); 
• a major challenge is its high logistics costs, owing to under-developed transport 
infrastructure and inadequate logistics facilities. Higher logistics costs tend to bring down 
the profitability of import, export, transportation and delivery services within the country. 
This implies a higher demand for cost-effective and efficient logistics services in Vietnam 
(Locus Bulletin, 2019), and  
• the EPI still faces challenges, including a shortage of medical staff majoring in 
immunisation in the grassroots level, inadequate vaccine supply in some localities, 
 
49 Prices for domestic vaccines produced by POLYVAC, VABIOTECH, and IVAC are dictated by MoH policy, and 
have remained largely static since 2008 (WHO, 2017: 17). Pricing and financing issues continue to be an 
important deterrent for more pro-active promotion of influenza vaccine uptake. 
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reduced funds and declining international aid, as well as poor public awareness of 
the importance of vaccination.50 
Capital support and framework 
Vietnam is a rapidly developing country. Vietnam was declared a middle-income country in 
2009 by the OECD. Countries like Vietnam transitioning to middle-income status increasingly 
bear the cost of both existing and new vaccines (Jit et al., 2015). Support from Gavi had allowed 
Vietnam to move forward in expanding their package of vaccines, and reaching remote areas - 
their exit between 2016 and 2020 will leave a gap in financing (ThinkWell, 2017: 5). The 
Government budget for immunisation confirmed in 2017 guarantees increased domestic 
financing for both vaccines and the cold chain through to 2020.51 
The National Regulatory Authority (NRA) of Vietnam reached WHO international standards for 
vaccine regulation in June 2015. The Drug Administration of Vietnam (DAV) issues a new 
drug registration within 180 days of an application being submitted. This makes the process 
much quicker than in the US and UK, although it is in line with other countries in Southeast 
Asia.52 By law, an extension to the current marketing authorisation should be issued within three 
months from the receipt of a complete application dossier.53 
The combined 5-in-1 vaccine to protect against DPT, HepB and Hib (Quinvaxem – has been 
sponsored free of charge and measles-rubella (MR) vaccine (WHO, 2017: 5). In 2015, Vietnam 
was the only country in the world running two vaccination systems: the EPI and the non-EPI 
vaccination service. The Government requested relevant authorities draw up a plan towards a 
united vaccination programme in the country by 2020. Initially, the Ministry of Finance 
developed a decree to define prices for the EPI and non-EPI vaccination services (Nhan Dan, 
2020). 
Pharma growth and vaccine access 
A recent GDP growth statistics report states that Vietnam is the fastest 
growing world economy, with a growth rate of 7.31% in 2019. It has surpassed the growth rate 
of other Asian economies including India and China, which stand at 4.5% and 6% CAGR 
respectively (Locus Bulletin, 2019). The DAV states that the pharmaceutical market of Vietnam 
was worth USD5.2 billion in 2020, with the growth rate of 12% per year.54 Market research firm 
 
50 Vietnam becomes vaccine self-sufficient. 15 December 2012: 
http://dtinews.vn/en/news/017002/26660/vietnam-becomes-vaccine-self-sufficient.html  
51 Anuradha Gupta, Deputy CEO of Gavi, the Vaccine Alliance. 29 September 2017: 
https://www.gavi.org/vaccineswork/prioritising-prevention-vietnams-vaccine-success-story  
52 For a new vaccine, or where the safety and effectiveness report of the drug is not available or insufficient, the 
DAV will grant a marketing authorisation with a three-year term. Within 12 months before the expiration date of 
the current marketing authorisation, the marketing authorisation holder may apply for an extension - Vietnam’s 




53 Regulatory, Pricing and Reimbursement Overview. 30 May 2020: https://pharmaboardroom.com/legal-
articles/regulatory-pricing-and-reimbursement-overview-vietnam/  
54 VietnamCredit: Vietnam’s pharmaceutical market worth more than USD 5 billion. 19 August 2020: 
https://www.febis.org/2020/08/19/vietnamcredit-vietnam-s-pharmaceutical-market-worth-more-than-usd-5-
billion/#:~:text=Market%20research%20firm%20IBM%20said,50%20per%20person%20in%202020.  
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IBM predicts that the size of Vietnam's pharmaceutical industry may reach USD 7.7 billion in 
2021 and USD16.1 billion in 2026. Vietnam has benefited from progressive Foreign Direct 
Investment (FDI) policies. Inflows to Vietnam rose marginally, reaching an all-time high of 
USD16 billion, with robust inflows into manufacture (Ginting, 2019; UNCTAD, 2020: 43). 
Almost 68% of the total FDI capital was invested in the manufacturing industry (Locus Bulletin, 
2019). The primary factor contributing to this massive leap in Vietnam’s economic growth is the 
amount of FDI coming in from investors around the world, especially the Republic of Korea, 
Japan, and Singapore. Another driving force behind Vietnam’s growing investment popularity is 
the country’s collection of free trade agreements (FTAs), such as the Comprehensive and 
Progressive Agreement for Trans-Pacific Partnership with Canada, and the 2018 EU-Vietnam 
FTA with European countries (Locus Bulletin, 2019; OECD, 2020: 16). 
Currently Vietnam has a small, but relatively impressive portfolio of vaccines and vaccine 
research projects. In late February 2014, Vietnam drew wide attention from the media, 
announcing its success in producing a diarrhoea vaccine for children for the first time. The 
successful production of Rotavin-M1 vaccine has helped Vietnam to become the fourth country in 
the world and second in Asia able to produce vaccines against rotavirus (Nhan Dan, 2020). 
According to the National Product Development Programme for human vaccine, Vietnam was 
predicted to produce and commercialize at least 7 vaccines by 2020.55 The country is moving 
towards wiping out measles, and there are plans for development of a 6-in-1 vaccine to protect 
from diphtheria, whooping cough, tetanus, polio, influenza type B and Hepatitis B.. 
Vaccine exports and imports 
Since 2012, Vietnam has been reporting trade surpluses more frequently, as exports growth 
have been stronger than imports. In 2017, trade deficits were recorded with South Korea, China, 
Taiwan, Thailand, Singapore and Argentina. Vietnam recorded trade surpluses with the United 
States, Netherlands, Hong Kong, United Kingdom, United Arab Emirates, and Austria.56 
Vietnam is ahead of most other Asian countries in this respect since it has always promoted an 
export-oriented growth strategy. A progressive FDI policy supports that. Geography helps too. 
Vietnam exports more to China than any of its competitors in part because it is located right next 
door (Ginting, 2019). It is expected that Vietnam will continue to develop vaccines catering to 
its domestic market before developing the capability to produce vaccines for export 
purposes, such as those for hepatitis B and human papillomavirus (HPV). Therefore, Vietnam 
will, therefore, continue to have a negative vaccine trade balance (EVBN, 2014: 32) 
• VABIOTECH now imports and provides some vaccines and biological products to meet 
the market’s demand such as: Mumps, Rubella, Meningococcal, and Varicella at 
favourable prices. In February 2021, the Deputy Minister of Health signed a decision to 
approve the conditional import and use of the vaccine developed by AstraZeneca and 
Oxford University. This is the first COVID-19 vaccine allowed for usage in Vietnam, which 
 
55 Vietnam makes efforts to produce 6 in 1 vaccines. 23 December 2015: https://english.vtv.vn/news/vietnam-
makes-efforts-to-produce-6-in-1-vaccines-20151227110300801.htm  
56 Vietnam Balance of Trade: https://www.fxempire.com/macro/vietnam/balance-of-trade  
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will be imported under the regulation on "emergency cases of disease prevention."57 This 
is a lesson learned from the worldwide A/H1N1 pandemic struck in 2009, when Vietnam 
waited for more than a year to receive imported vaccine (Regan, 2018). Vietnam requires 
all imported biological products and new batches of vaccines to undergo quality 
testing by the National Institute for Control of Vaccine and Biologicals which 'does not 
have the capacity to effectively conduct such tests'. Therefore, these requirements only 
serve to delay the time needed to launch pharmaceutical products in Vietnam (EVBN, 
2014: 41). 
Positive spillover effects 
There is limited evidence of positive spillover effects due to local vaccine manufacturing. 
Improving Avian Influenza-Highly Pathogenic (HPAI) control in commercial poultry sector could 
have positive spillover effect on the epidemiological situation of the disease in native and 
backyard poultry.58 The only evaluation of Vietnam's EPI using two separate approaches shows 
that it has made a substantial impact on mortality, and is very likely to be cost-effective (Jit et al., 
2015).  
Skills development 
All four national factories have qualified staff to research, and produce vaccines with 
international standards for the EPI (Nhan Dan, 2020). For example, DAVAC specialises in 
technology transfer and support, scientific research and staff training at home and abroad. In 
2016, the MR vaccine was produced in Vietnam by POLYVAC under a technology-transfer 
project launched by the Japan International Co-operation Agency (JICA). Vietnam also has a 
good education system considering its level of development capable of producing an ample 
quantity of skilled labour that can participate in a wide range of manufacturing (Ginting, 2019). 
PATH supported IVAC as it worked to develop influenza A/H1N1 and A/H5N1 pre-pandemic 
vaccine candidates as well as a low-cost, seasonal influenza vaccine candidate. This work built 
on previous efforts in which PATH and WHO helped IVAC ready its vaccine production facility for 
influenza vaccine manufacture and clinical development. PATH has also worked closely with 
Vietnam’s MoH to build a supportive environment for influenza vaccine development and use. 
PATH also helped VABIOTECH obtain a commercial manufacturing license for a cell line suitable 
for influenza virus vaccine production, conducted technical trainings, and purchased equipment 
and supplies to support development of the cell based GMP process (PATH, 2018: 7).  
7. Brazil 
The Brazilian vaccine manufacturers' perspective is very positive, because it relies on the 
National Immunization Program (PNI), which is considered one of the best and most complete 
 
57 Health Ministry approves first COVID-19 vaccine in Vietnam. 2 February 2021:  
https://tuoitrenews.vn/news/society/20210202/health-ministry-approves-first-covid19-vaccine-in-
vietnam/59118.html  
58 Modeling the effectiveness of avian influenza vaccination strategies in Vietnam - evaluation of the added value 
of day-old chick vaccination in hatcheries: 
https://umr-astre.cirad.fr/content/download/5568/41770/version/2/file/EVACs_Vietnam_summary.pdf  
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among emerging countries (Homma, 2009). There are two main actors focused on human health 
(Homma, 2009): 
• The Immunobiological Technology Institute (Bio-Manguinhos), from the Oswaldo 
Cruz Foundation/Fiocruz (MoH), which develops and produces vaccines (such as: 
DTP + Hib, meningitis AC, OPV, triple viral, yellow fever), and biopharmaceuticals 
(erythropoietin, interferon alfa 1b), especially for the national health programmes, and 
• The Butantan Institute (São Paulo State laboratory), also in charge of developing and 
producing vaccines (DTP, DT, HBV, influenza) for the public system, and immune 
serum (anti-snake, anti-toxin). 
In spite of a significant and increasing role for some Brazilian universities, research institutes and 
companies, the number of patents for vaccines in the country is still low, indicating the need 
for a national strategy supporting innovation and technological development. Like other 
developing countries, the main challenge for Brazil and other is to accelerate and streamline 
the procedures of their national patent offices (the National Institute of Industrial Property 
[Instituto Nacional de Propriedade Industrial, INPI] in the case of Brazil) (Possas et al., 2015). 
Brazil local companies has been stuck in the grind of generics manufacturing59, unable to 
produce notable advancements in vaccine R&D (Parrish, 2020). However, the industry could be 
approaching a turning point due to the COVID-19 epidemic.  
Capital support and framework 
The research, development and production of immunobiologicals in Brazil, especially vaccines 
for human use, is mainly supported by Governmental institutions linked to the Ministry of 
Health (MoH) as part of a strategy that prioritises the public sector for access to vaccines and 
other biologicals that are regarded essential for the population (Homma, 2009). However, recent 
research shows the need for progress in the Brazilian national strategy to link domestic 
production, technological capacity-building, and innovation in the vaccine sector to help 
guarantee universal access to health in Brazil (Gadelha et al., 2020). 
Both Institutes enjoy a de facto monopoly on the large Brazilian public market, prices are set by 
the MoH, and track the prices charged for similar vaccines by the PAHO Revolving Fund or 
UNICEF (Milstien et al., 2007). The international non-profit PATH assisted Instituto Butantan’s 
efforts to achieve WHO PQ status60 of its seasonal, trivalent inactivated influenza vaccine, which 
is already licensed for use in Brazil (PATH, 2018: 7). However, investment in Brazil remains risky 
 
59 The pharma market in Brazil is divided between generics and branded medicines. According to Sindusfarma, 
the Brazilian Ministry of Economy registered 418 pharma manufacturing plants in the country in 2018. EY 
estimates that nearly half of the industry’s revenue is concentrated in its top 10 companies. Of those 10, six are 
Big Pharma companies and the other four are local. Generally speaking, while Big Pharma companies control the 
market for branded medicines in Brazil, almost all of the local companies stick with the generics market.  Local 
companies have been successfully managing in this environment, but it is not a very easy market to play in 
(Parrish, 2020). With access to free health care guaranteed by SUS, Brazil’s Government and hospitals have a 
30% portion of the local low-cost drug market, while the other 70% of drugs are sold through commercial 
pharmacies. 
60 PQ enables a vaccine to be available for procurement by United Nations agencies and Gavi for use in low-
resource countries and is key for reaching global markets. 
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because of some negative factors, including cumbersome and complex taxation, bureaucratic 
delays, as well as heavy and rigid labour legislation.61 
Pharma growth and vaccine access 
Brazil is one of the fastest growing global economies. Brazil is not only being the biggest 
country in Latin American but also the most influential. It is the second most attractive BRIC 
(Brazil, Russia, India, China) nation62 in the eyes of the pharma industry (Chhabara, 2010).63 
Brazil is an attractive market for international investors due to several factors: a domestic market 
of nearly 210 million inhabitants, availability of easily exploitable raw materials, a diversified 
economy that is less vulnerable to international crises, and a strategic geographic position that 
allows easy access to other Latin American countries. 
It enjoyed huge economic growth in the first half of 2010 emerging from the downturn faster than 
its closest Latin American rivals in terms of demand for pharmaceuticals (Bates, 2011). 
According to Chamber for Pharmaceutical Market Regulation (CMED) data, the Brazilian 
pharmaceutical market’s turnover in 2017 was approximately BRL69.5 billion (approximately 
USD22 billion), or 9.4% nominal growth over the year 2016 (Gadelha et al., 2020). 
The Brazilian pharma market outperformed the Latin American average in Q1 of 2020 with a 
growth of 8.2% in real terms (inflation adjusted), according to IQVIA. As a general rule, the 
pharma sector in Brazil has never been a major contributor to the world’s advancements 
in R&D, save for one exception - vaccines (Parrish, 2020).  
The Instituto de Tecnologia em Fármacos Farmanguinhos is currently the largest official 
pharmaceutical laboratory linked to the MoH. Farmanguinhos plays a strategic role by acting as 
a regulator of market prices of antiretroviral vaccines. Thus, the Institute stands out in the 
struggle for cost reduction, which contributes to more Brazilians have access to public health 
programmes. Currently, the institute can produce more than 50 different types of medicines, 
according to the needs of SUS. 
Bio-Manguinhos (Immunobiological Technology Institute) is a unit of the Government-funded 
Oswaldo Cruz Foundation (Fiocruz). In October 2013, Fiocruz announced that it was going to 
develop an affordable bivalent measles and rubella (MR) vaccine with the support of the Bill & 
Melinda Gates Foundation. The Brazilian MoH allocated funds to support this plan, including 
USD727 million for the construction of a plant at the Bio-Manguinhos site to produce the vaccine. 
In December 2020, an agreement with the Government of the State of Rio de Janerio was 
announced for the Industrial Complex of Biotechnology in Health (Cibs) to be built, in the 
Industrial District of Santa Cruz, Rio de Janeiro. The new plant aims to enable the production 
of new vaccines, such as the bivalent vaccine (for measles and rubella), clinical studies of 
 
61 https://santandertrade.com/en/portal/establish-overseas/brazil/foreign-investment 
62 These four developing countries are at a similar stage of newly advanced economic development, on their way 
to becoming developed countries.  
63 The pharma sector in Brazil underwent radical change as the political restructuring, deregulation, and 
decentralisation of power that followed the end of the military coup in 1988. This resulted in a breakdown of state-
led development and production. The re-democratisation process led to a new federal constitution that introduced 
state-funded healthcare for all: the first initiative of its kind, not only in Brazil but also across the BRIC nations. 
The integrated/unified health system, known as SUS, focused on prevention offering comprehensive cover 
providing a basic level of care to all, in addition to more costly treatments such as antiretroviral therapy for HIV 
(Bates, 2011). 
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which were recently concluded by Bio-Manguinhos, and meningococcal C, which is in an 
advanced stage of studies phases II/III, in addition to new vaccine presentations from the 
Institute’s portfolio (number of doses/bottle), to meet different needs of the health system.64 In 
January 2021, Fiocruz officially submitted the application to register the COVID-19 vaccine to 
ANVISA, which will allow the Oxford-AstraZeneca immuniser COVID-19 vaccine across the 
country, which will be distributed through the Ministry of Health’s PNI.  
Case study: An innovative moderate volume public sector manufacturer partnering with 
an MNC (BioManguinhos and Butantan, Brazil- Cuba) 
Positives: The Brazilian manufacturers, BioManguinhos and Butantan, have invested in R&D, 
have knowledge of intellectual property concerns, are supported by a well-functioning national 
regulatory authority, and are together providing the majority of Brazil's public sector vaccines. 
This success has been based on a long history of manufacturing, plus a strong Government 
interest in strategic planning. Although only BioManguinhos currently produces PQ products 
(yellow fever vaccine and meningitis AC polysaccharide vaccine – in collaboration with Cuba's 
Findlay Institute, another example of South–South coopera-tion), both have attracted the 
attention of large vaccine MNCs, who have transferred vaccine production technology starting 
from filling of imported bulk vaccines. BioManguinhos has had such an agreement in force with 
GSK for many years for filling of oral poliovirus vaccine, and recently concluded one for measles-
mumps-rubella vaccine. Also through a GSK agreement, they have progressed to full scale 
production of Hib vaccine, and will shortly commence filling of imported pneumococcal conjugate 
bulks as a step towards a full technology transfer of that vaccine. Sanofi Pasteur has had a 
similar arrangement with Butantan, which has now started full scale influenza vaccine production. 
The advantages of such agreements are that they allow the country to benefit from a new 
vaccine technology sooner, and will eventually result in national ownership of the 
technology.  
Challenges: Disadvantages are that the prices may be higher than could eventually be attained 
by these national manufacturers, and they are not able to be offset by export sales, which are 
controlled by the MNC. 
Vaccine exports and imports 
The country has actively exported yellow fever vaccine since 2002 and meningitis AC vaccine 
since 2007, having covered more than 60 nations (Homma, 2009). Once Butantan could produce 
up to 180 million DTP Triple vaccines (diphtheria, tetanus, pertussis) (or its combinations) per 
year, it began exports (Raw & Higashi, 2008: 160).  
As a result of Government support, 83% of the vaccines required in 2007 were provided by 
national vaccine producers and only 17% were imported, mainly to reference centres for special 
vaccines that were used for special patients. Perspectives have positively increased due to the 
Government's policy of making internal investments, not only to avoid the external 
dependence of products for public health, but also to strengthen the Brazilian industrial sector 
related to biotechnology (Homma, 2009). 
According to the Brazilian Constitution, plasma and its by-products cannot be sold - the plasma 
is therefore exported for processing as an alternative (Raw & Higashi, 2008: 168). Nucleic 
acid-based technologies support fast and flexible vaccine development and production (Rauch et 
 
64 https://uk.finance.yahoo.com/news/global-meningococcal-vaccine-market-brand-111900272.html  
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al., 2018). Since all vaccines can be produced using the same basic components, manufacturing 
of several vaccines can take place in one established facility cutting both costs and time of 
vaccine production dramatically.  
Imports of finished products, semi-finished products, vaccines, blood products, and other 
pharmaceutical products reached USD7.3 billion - an increase of 1.4% compared to the 
previous year.65  
However, with Brazil relying on generic manufacturing to supply its demand for lower cost 
drugs, the industry has become linked to API imports from India and China. Ernst & Young 
(EY) and PricewaterhouseCooper (PwC) both estimate that Brazil currently imports about 90% of 
its APIs, leaving the supply chain vulnerable to disruptions in the quantity and quality of its drug 
ingredients (Parrish, 2020). So far, Brazil has not experienced any supply disruptions during the 
COVID-19 pandemic, but the situation has exacerbated concerns about shortages, and 
increased pressure on the industry and Government to find solutions.66 
Positive spillover effects 
There is limited evidence on positive spillover effects of local vaccine development. Only 
Baptista et al. (2006) estimated a 61.6% (95% CI 12.8%, 83.1%) risk reduction in studies of 
spillovers in households with individuals diagnosed with pertussis who were vaccinated versus 
those unvaccinated for pertussis (the vaccine efficacy for infectiousness). 
Skills development 
Development of vaccines through technology transfers has been essential to the country’s 
universal immunisation programme (IFPMA, 2015: 7). Five partnerships which supported 
technology transfer in Brazil in 200667 included agreements for the transfer of knowhow, but no 
licences for patents rights. Conversely, an agreement for the transfer of dengue vaccine 
technology, from the US National Institutes of Health to Butantan in Brazil, included a licence for 
patent rights but no explicit authorisation for the transfer of knowhow. PATH also provided 
Butantan with guidance on improving its quality management system and developing a 
pharmacovigilance system, and also provided support for the development of a pre-pandemic 
inactivated influenza A/H7N9 vaccine candidate (PATH, 2018: 7). 
Much of 2010 was spent forging close links with the biotechnology sector and continued open 
dialogue with the Federal Medicine Council (Conselho Federal de Medicina, CFM) to foster ties 
between industry and healthcare professionals, with the aim of developing patient and public 
health initiatives (Bates, 2011). The creation of the Health Economic-Industrial Complex 
(HEIC) in the early 2000s has guided and amplified biotechnological research and 
pharmaceutical, vaccine and diagnostics production, and has helped to create jobs and 
national economic growth (WHO, 2011: 39). Butantan has developed its own technology and 
commands production. This type of control required designing and building new production 
 
65 Profile of the pharmaceutical industry and relevant sector aspects: 
https://sindusfarma.org.br/uploads/Publicacoes/Perfil_IF2020_ING.pdf  
66 Eliane Kihara, a partner with PwC. 
67 Milstien JB, Gaulé P, Kaddar M (2007). Access to vaccine technologies in developing countries: Brazil and 
India. Vaccine, 25(44), 7610–7619: http://dx.doi.org/10.1016/j.vaccine.2007.09.007  
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plants. Butantan constantly teaches Brazilian builders what is needed, such as filtered air to 
maintain sterility and even teaches Brazilian companies to produce equipment that had always 
been imported (Raw & Higashi, 2008: 157).  
8. Cuba  
Cuba currently produces 8 of the 12 vaccines in its National Immunisation Programme 
(Marsh, 2020). Cuba bet on biotechnology very early, opening the first research - manufacturing 
facility in the country in 1981.68 Since its establishment in the mid-1980's, the Cuban biotech 
sector has developed a meningitis B vaccine, and today exports the world's most effective 
hepatitis B vaccine to more than 30 countries. Recently, it developed the first synthetic vaccine 
for the prevention of pneumonia and meningitis, which is much cheaper than what is offered by 
Western pharmaceutical companies (Fawthrop, 2004). More recently, Cuba has developed 
a vaccine for lung cancer (CIMAvax-EGF), and produced a number of innovative drugs and 
vaccines as a result of advances in its biotech sector, including haemophilus influenzae type b 
(Hib) vaccines (O’Farrill, 2018).  
Nowadays, most of the biotech industry is concentrated in BioCubaFarma, a state holding 
created in 2012 with the Government’s economic reforms. This organisation of Biotechnology 
and Pharmaceutical Industries manages the country’s efforts toward manufacturing medicines, 
diagnostics and medical equipment and providing high quality life science services to improve 
people’s health. Another centre of excellence is the Pedro Kouri Institute of Tropical Medicine 
(IPK) which works closely with the WHO in Geneva (Fawthrop, 2004).  
However, some of the attractiveness of investing in Cuba include the country's high potential in 
tourism, qualified and inexpensive labour, and its geographical location. However, the Cuban 
economy is vulnerable to external factors, such as climate, and commodity prices. Poor 
infrastructure, bureaucracy, Cuba’s Soviet-style economy, the country's dual currency 
system, and tighter US restrictions, still hamper foreign investors.69 Also, cash-strapped 
Cuba may also struggle to buy raw materials for large-scale vaccine production (Marsh, 
2020). 
Capital support and framework 
Former leader Fidel Castro championed a 100% home-grown biotech sector in the 1980s. 
Cuba has invested a lot of cash into its state-owned biotech industry, partly so Cuba could 
become more vaccine self-sufficient in the face of a US trade embargo. As a result of both 
economic necessity and of Cuba’s publicly stated values - has been producing affordable 
medicines. It is supported by Cuba’s medical philosophy, which prioritises prevention - the only 
viable path for a poor country to provide universal healthcare affordably (O’Farrill, 2018).  
BioCubaFarma has consolidated a deep product pipeline that includes prophylactic and 
therapeutic vaccines.70 BioCubaFarma’s strength and value derive from a combined network of 
 
68 https://www.nature.com/articles/d43747-020-00522-5  
69 Foreign direct investment (FDI) in Cuba: https://www.nordeatrade.com/en/explore-new-
market/cuba/investment 
70 BioCubaFarma: bringing Cuban biopharma to the world: https://www.nature.com/articles/d43747-020-00522-5  
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34 companies and institutions under one umbrella that collaborate on maximising the impact of 
their R&D programmes in the biotechnological and pharmaceutical space. Eight institutions 
constitute the core of this network,71 three of which are involved with vaccines:  
• the Center of Genetic Engineering and Biotechnology (CIGB): founded in 1986, it is 
one of 34 companies and institutes that constitute BioCubaFarma. It develops, 
manufactures and commercialises human and veterinary vaccines. CIGB makes 60% of 
medicines used in Cuba, and 8 of 12 vaccines;72 
• the Center of Molecular Immunology: the CIM specialises in the development and 
manufacture of products for the diagnosis and treatment of diseases related to the 
immune system, and of molecular vaccines for cancer immunotherapy, and 
• the Finlay Institute: the IFV is Cuba’s pre-eminent vaccine research and production 
centre. The institute co-ordinates research in immunology, molecular biology, and applied 
microbiology to develop novel vaccines and the fermentation processes needed for their 
production. Among IFV’s top accomplishments is the development of the first vaccine in 
the world against meningitis B almost 30 years ago. 
Cuban vaccine manufacturing is a 100% Government investment. The Ministry of Public 
Health (MINSAP) is responsible for ensuring the stability of drug prices for the population 
and has approved prices since 1988, using a methodology endorsed by the Ministry of Finance 
and Prices, in which the Government of Cuban subsidizes part of the price, as necessary (WHO, 
2015a: 43). The Government of Cuban, through MINSAP, has ensured the financial sustainability 
of the Cuban regulatory agency (CECMED) as an essential component of the national health 
system with a view to developing local production of drugs and other health technologies that 
meet international standards (WHO, 2015a: 49). Income generated by vaccine sales abroad 
will pay for health care, education, and pensions in Cuba, which is what happens with 
exports of medical services and medicines.  
Cuba’s Ministry of Foreign Trade and Foreign Investment (MINCEX)73 is responsible for 
directing, carrying out and monitoring implementation of the Cuban Government policy on trade, 
investment and collaboration abroad. Its main objectives are to diversify its business partners 
and work towards reorganising trade policy in pursuit of favourable markets for its exports and 
the diversity and competitiveness of its export items. Cuba has trade relations with over 170 
countries (WHO, 2015a: 32). 
Pharma growth and vaccine access 
Biotechnology is one of Cuba’s largest sources of foreign exchange. However, no reports 
were found on the contribution of the pharmaceutical sector to gross domestic product (GDP) 
(WHO, 2015a: 35). Havana's Finlay Institute (formally the National Center for Development of the 
Meningococcal Vaccine) is a leader in Cuban health technology, producing various vaccines 
such as the tetanus vaccine vax-TET and a combination vaccine against tetanus and 
 
71 https://www.nature.com/articles/d43747-020-00522-5  
72 A socialist approach: https://www.thenews.com.pk/print/787090-a-socialist-approach  
73 Approved by Decree Law 264/2009, the purpose and essential mission of MINCEX are to prepare and propose 
to the Cuban Government a comprehensive policy on foreign trade activity, the creation of joint ventures, and 
economic co-operation with other countries, foreign organisations and associations. 
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diphtheria. It entered into a deal allowing major drug MNC GSK to license its discovery in order 
to facilitate the first entry of a Cuban medical product into the more lucrative Western market 
(Fawthrop, 2004). 
The biotechnology and pharmaceutical industries have been funded by the State through 
different plans that have changed over the years. In the case of biotechnology, in its infancy 
funding was provided directly by the State. In 2001 changes were introduced, and a self-
financing plan was adopted, specifically for current expenditures; investments were the exception 
and had to be approved centrally. In late 2008, another form of financing was introduced, which 
had to be approved by the Ministry of Economy and Planning (WHO, 2015a: 28). 
Today, Cuba's pharmaceutical industry is increasing in strength. Cuba’s entirely state-
owned biopharmaceutical industry has been remarkably successful (O’Farrill, 2018). It is 
distinctive because it is owned by the state and not supported by speculative financing.74 
BioCubaFarma has an extensive global presence through mixed capital companies in China, 
Spain, Thailand, and Singapore, solely Cuban-owned companies in Venezuela, Ecuador, Brazil, 
and Mexico, a representative office in China, and a branch office in Colombia.75 The country is 
developing four COVID-19 vaccines in parallel to help with access: The Finlay Institute of 
Vaccines is leading on Soberano 02, and also Soberano 01;76 two more, Abdala and Mambisa, 
are being developed by the Centro de Ingeniería Genética y Biotecnología. Both the institutes 
are funded and operated by the Cuban Government. 
The US embargo, unlikely to be lifted soon, will continue to put legal obstacles for American and 
other foreign companies. The Government favours investments that provide advanced 
technology and contribute to the infrastructure. In 2015, Cuba passed a new law Foreign 
investment Act, which introduced tax incentives for foreign investors, and created a special 
economic zone (SEZ) with tax and customs breaks, with the hope of attracting more foreign 
capital to boost its state-dominated economy. However, the latter cannot directly recruit 
employees. The new legislation opens most of the economy to FDI, except in health, education, 
media and the military (UNCTAD, 2020: 218). However, the lack of statistical transparency 
prevents the gathering of reliable data on the amount of FDI inflows.77  
The greatest challenge to the pharma industry is the yearly review of drug price controls. 
Every year, drug price increases are limited by CMED (Câmara de Regulação do Mercado de 
Medicamentos), an arm of Brazil’s health regulatory body known as ANVISA (Parrish, 2020). 
Vaccine exports and imports 
Many countries, including Spain, Canada, Mexico, Italy and Venezuela continue to trade and 
invest in Cuba. Therefore, vaccine manufacture has become a major part of the economy. 
 




76 Guenot M (2021). Cuba is working on a homegrown COVID-19 vaccine program. It has a history of fighting 
disease without help from the West. 15 February 2021: https://sports.yahoo.com/cuba-working-homegrown-
covid-19-123607295.html  
77 Foreign direct investment (FDI) in Cuba: https://www.nordeatrade.com/en/explore-new-
market/cuba/investment 
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Cuba has exported hundreds of millions of vaccines to more than 40 countries (Marsh, 2020). 
The Government of Cuba established R&D institutes that are designed to also facilitate 
manufacturing of respective products (research-production centres or full cycle institutions), not 
only to meet local health needs but targeting export markets as well (WHO, 2015a: 3). 
Because of the absence of the private pharmaceutical sector in Cuba, all health needs are met 
through public or state-controlled institutions. Most of the drugs that are produced 
domestically are not imported in the country, and the price stability is ensured through 
subsidies by the state and are established through the Ministry of Finance and Prices 
(WHO, 2015a: 4). 
Positive spillover effects 
Through the holistic approach with a long-term perspective to promoting and supporting local 
capacity for pharmaceutical manufacturing, Cuba has developed a good public health strategy 
with indicators comparable to those of industrialised countries despite limited resources. To date, 
local production has contributed 65% to the local health needs, drug prices are generally low 
compared to the income level of the Cuban population, and the human development index 
is now comparable to that of the developed countries (WHO, 2015a: 4). 
Skills development 
Since 1959, Cuba has invested significant financial resources in the training of human 
resources and science and technology development. This has influenced the achievements 
of the Cuban pharmaceutical industry and the population’s access to health technologies. In the 
1990s, Cuba accounted for 11% of doctorate-level Latin American scientists. Cuban scientists 
work in the 50 biomedical research and production facilities which together make up Cuba’s 
state-owned BioCubaFarma Corporation. At the end of 2013, CIGB had more than 21,600 
employees, 6,158 of whom were university graduates Of these, 270 had PhDs and 1079 had 
master’s degrees (WHO, 2015a: 18). Hundreds of them highly-skilled professionals deeply 
integrated within several research-production activities (O’Farrill, 2018). With a research 
workforce of more than 1,500, the centre is one of the pre-eminent biotechnology organisations 
in the Latin American region.78 Finlay Institute, one of 20 research centres and 32 companies, 
employs some 20,000 people that make up the state-run BioCubaFarma corporation (Marsh, 
2020). IPK also brings together highly qualified professionals from Harvard Medical School who 
make up a multidisciplinary team for the comprehensive care of patients (Fawthrop, 2004). 
In 1986, US-based biotechnology company Chiron developed the technology to obtain a 
genetically engineered (or DNA recombinant) hepatitis B vaccine; that same year, the Cuban 
recombinant vaccine was developed using a cheaper method. While not popularly understood 
outside the country, Cuba’s biopharma achievements have been recognised by the international 
scientific community. In 2005, the Laboratory of Synthetic Antigens, a small lab that belongs to 
the faculty of chemistry of the University of Havana, won the World Intellectual Property 
Organization (WIPO) Gold Medal Award for developing the world’s first synthetic vaccine 
(Quimi-Hib) against haemophilus influenza type b (or Hib) (O’Farrill, 2018). 
 
78 https://www.nature.com/articles/d43747-020-00522-5  
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Nowadays, Cuba has become a global leader in the South-South transfer of technology, 
helping low-income countries develop their own domestic biotech capabilities, providing technical 
training, and facilitating access to low-cost lifesaving drugs to combat diseases such as 
meningitis B and hepatitis B (WHO, 2015a: 3). The success of Cuban R&D as well as local 
manufacturing capacity can also be measured in the light of numerous technology transfer deals 
it has secured with other countries including Algeria, India, Brazil, China, South Africa, Mexico, 
Argentina, Vietnam, and Malaysia (WHO, 2015a: 4). 
State-run media have run lengthy profiles of researchers working at Finlay Institute (Marsh, 
2020). Scientists are hailed as heroes in Cuba, a prestige that helps limit brain drain 
despite low salaries and difficult conditions, as Cuban researchers contend with US 
sanctions that hamper international collaboration and the purchase of supplies (Marsh, 2020). 
However, O’Farrill (2018) found that the Government needs to better understand behaviour in 
innovative organisations, and which measures will encourage or discourage employee 
motivation. Important wage increases for highly-skilled professionals have taken place since 
2014 especially in the health sector, benefiting more than 440,000 healthcare workers, who in 
most cases saw their salaries grow by more than 100% (O’Farrill, 2018). However, these wage 
increases appear to be negatively impacting the motivational balance of the biotech 
workforce. The industry has seen 40% of its workforce quit over the last two years.  
9. Mexico  
Over the course of the twentieth century, state builders created several institutions devoted to 
the production of vaccines - including the Institute of Hygiene, the Laboratory of the 
Pharmaceutical Industry, the National Institute of Virology and the Central Laboratory of 
Reagents - all attached to the MoH (Carrillo, 2017: 140).  
The creation of GAP has allowed WHO to directly support vaccine manufacturers in 14 countries, 
including Birmex, to acquire the capacity to produce inactivated or live attenuated influenza virus 
(LAIV) vaccine for the population (WHO, 2015b: 1). Vaccination against influenza is a political 
priority, and there is political will for vaccine production in the country as a means to guarantee 
the needed supply at a low price. For the purchase of influenza vaccines in particular, the MoH 
has a multiannual vaccine purchase agreement with Birmex (for 15 years, starting in 2008). The 
agreement states that the MoH must purchase the vaccine through Birmex, with the maximum 
price set to be equal to the one offered by PAHO’s Revolving Fund. 
However, Mexico has had repeated stopping and starting of vaccine production under 
conditions of revolutionary instability (Carrillo, 2017: 138). Nowadays, domestic vaccine 
development has practically disappeared. It was not intellectual or technical incapacity that 
influenced the disappearance of national vaccine production but rather economic, political and 
cultural factors, including strong governments, revolution and civil war, controversies among 
physicians, rebellions against vaccines, accidents, and the creation, reorganisation and 
dissolution of institutions (Carrillo, 2017: 140). 
• approval by Mexico’s pharmaceutical trade association  COFEPRIS is a challenge 
for companies looking to gain market access in Mexico. The approval process for 
COFEPRIS is relatively quick, usually taking around six months. However, applications 
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for inclusion on Mexico’s formularies are often subject to delays of up to two years 
after registration has been completed;  
• getting included on the country’s three major formularies is an even more 
important part of achieving market penetration in Mexico. However, the difficulties in 
this area need to be taken into account (Steele, 2013). Once a drug has been included 
on the national formulary, it must then seek inclusion on the Mexican Institute of Social 
Security (Spanish: Instituto Mexicano del Seguro Social, IMSS) formulary and the 
formulary of the Institute for Social Security and Services for State Workers (ISSSTE); 
• Mexico has repeatedly asked for price negotiations in Mexican pesos, however, influenza 
vaccine prices are currently negotiated in US dollars; a situation that threatens 
sustained vaccination when there are significant changes in the exchange rate 
(WHO, 2015b: 4). Once the price is set, the budget is calculated in Mexican pesos (using 
the official exchange rate for the day) but the payment is not made until the vaccines are 
delivered (using the day’s exchange rate), and 
• vaccine price per dose continues to be an important threat for sustained 
vaccination (WHO, 2015b: 4). Research shows that without justification, influenza 
vaccines against pandemics have been sold at a much higher price than seasonal 
vaccines and denounces the transfer of the responsibilities of the company that markets 
the product to the governments with regard to the compensation for serious illness or 
death from the vaccine.79 
Capital support and framework 
Domestic vaccine production has been a political priority, because politicians saw that 
imports were expensive and also because national security dictated protecting public health 
(Carrillo, 2017: 135). The state-owned Biological and Reagents Laboratories of Mexico LLC 
(Birmex),80 is the company responsible for the production, commercialisation, distribution, and 
investigation of biological and reagents in Mexico since in 1999. In 2007, in the context of the 
Global Pandemic Influenza Action Plan (GAP) of WHO to increase vaccine supply worldwide, 
Birmex was selected by WHO to be part of the manufacturers grantees. Since then, Birmex has 
received five grants (2007, 2009, 2011, 2014 and 2015), representing 8% of the total 
investment.81 
Vaccine manufacture relies on funding by public-(foreign)private partnerships. Public 
production assured that currency remained in Mexico, while private manufacturing increased 
capital flight. Public production concentrated on products that resolved local problems, which was 
of little or no concern to private production. In public production, all products were generated 
within the country, while private production required importing finished products or products 
shipped in bulk. In the public sector, the technical and administrative personnel were Mexican, in 
the private sector they were foreigners (with the exception of Myn y Zapata Laboratories) 
(Carrillo, 2017: 136). Access to viral immunity has been in the hands of very few business 
 
79 FORCADES, 2010, p. 246 in Tamez et al., 2016 : 16. 
80 http://www.birmex.gob.mx  
81 INFLUENZA VACCINE PROJECT AT BIRMEX: 
https://www.who.int/phi/8thPartnersMtg2015_Birmex_poster.pdf  
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firms, including national and international entities and institutions.82 MNCs are responsible 
for the design, development, production and marketing of vaccines in a market that handles 
about USD10 billion in annual sales. On the other hand, there are multilateral institutional actors 
(international organisations and national detection centres) that have the power to concentrate 
the updated samples and recommend to WHO the strains that will serve as the basis for the 
annual production of vaccines (Tamez et al., 2016: 17). 
Pharma growth and vaccine access 
Mexico's pharmaceutical industry generates revenues of approximately USD11 billion, making it 
the 11th largest pharma market in the world. In Latin America, Mexico comes in second after 
Brazil, which leads the region with USD16 billion.83  
Vietnam’s pharmaceutical sector has been overwhelmed by foreign companies in patent and 
specialty drug segments (EVBN, 2014). However, FDI inflows to Mexico decreased by 5% to 
USD33 billion. As usual, the manufacturing sector absorbed almost half of FDI inflows (47%), 
with USD16 billion driven by the automotive industry (representing 21% of FDI) (CITAD, 2020).  
Mexico had achieved self-sufficiency in vaccine production, control, storage and distribution, 
except in the case of the poliomyelitis vaccine, whose production did not always fulfil national 
demand, and by the end of the 1980s was exporting biological products (including vaccines, 
mainly for rabies) to fifteen countries in the Caribbean as well as Central and Latin America 
(Carrillo, 2017: 135). However, from the standpoint of self-sufficiency, not enough vaccines 
have been produced since 1998 (Tamez et al., 2016).  
Vaccine export and imports 
Birmex is responsible for the export of vaccines. A Brazilian Sanofi plant provides bulk influenza 
vaccines to Birmex.84 Each year, Birmex imports, controls and distributes nearly 20 million doses 
of seasonal influenza vaccine, which are delivered to the institutions of the Health Sector 
(Mexican Social Insurance Institute, Institute of Social Security and Services of State Workers, 
Popular Insurance, States’ Departments of Health, Pemex health services and the Armed 
Forces, etc.); these are applied during national vaccination campaigns (Tamez et al., 2016: 13). 
It plans to import about 870,000 doses of AstraZeneca's COVID-19 vaccine from India in 
February, as well as producing it locally.85 The Government also states that it is not opposed to 
private companies buying COVID-19 vaccines to distribute to patients who want to pay for the 
shots.86 
 
82 Macías-Richard C (2010). Respuestas institucionales y corporativas a la pandemia de 2009: América Latina 
ante los actores multinacionales en la producción de medicamentos. Desacatos, Guadalajara, 32, 63-88. 
83 The Pharmaceutical Industry in Mexico - New Challenges, New Leaders: 
https://www.russellreynolds.com/sites/default/files/mexican_pharm_trendsreport.pdf  
84 Raw I (2019). Developing Countries Can Innovate and Produce Vaccines: The Case of Butantan in Brazil: 
https://www.intechopen.com/books/vaccines-the-history-and-future/developing-countries-can-innovate-and-
produce-vaccines-the-case-of-butantan-in-brazil  
85 Mexico to import 8.70 lakh doses of AstraZeneca vaccine from India. 30 January 2021: 
https://www.indiatoday.in/coronavirus-outbreak/story/mexico-to-import-astrazeneca-vaccine-from-india-1764175-
2021-01-30  
86 Mexico might allow private firms to buy, distribute vaccines. 29 December 2021: 
https://abcnews.go.com/International/wireStory/mexico-private-firms-buy-distribute-vaccines-74937990  
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Positive spillover effects 
There is evidence exploring the possible spillover effects of the Programa Nacional de 
Educacion, Salud y Alimentacion (PROGRESA) programme on the wider community, which 
offered conditional cash transfers (CCTs) in Mexico (Handa et al., 2001; Avitabile, 2012). 
Significant spillover effects appear to exist among children ages 11–12 years, especially 
continuation rates for girls (almost 10 percentage points higher). There is also existence of a 
significant spillover effect of PROGRESA on the health care behaviour of non-beneficiary 
households. However, results indicate that this spillover effect takes time to manifest itself 
(Handa et al., 2001: 20). Health interventions can generate spillover effects on the demand for 
healthcare among individuals who do not belong to the original target group (Avitabile, 2012: 28). 
Increased demand for Papanicolaou cervical cancer screening among women in rural Mexico 
was also found (Avitabile, 2012). 
Skills development 
The main component of the agreement was an intensive technology transference package for 
filling/packing the vaccine in a multipurpose plant build by Birmex in the State of Mexico (Tamez 
et al., 2016). In addition, the influenza project was supported by the Mexican MoH, 
complemented by Birmex's own budget and grants from the WHO developing country influenza 
technology transfer project (Ponce-de-Leon et al., 2011). However, Mexico is dependent on 
foreign institutes and manufacturing laboratories for training and models of manufacture 
(Carrillo, 2017: 138). In 2008, Birmex established a joint venture with Sanofi-Pasteur for the 
production of influenza vaccine in Mexico.  
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